AbbVievsArcutis Biotherapeutics

ABBV and ARQT stock compared: price, dividend, valuation and results, from SEC filings.

ARQT

Arcutis Biotherapeutics, Inc.

$27.82

Value $3.4B

-1.57%
ARQT's page

AbbVie (ABBV) has a market value of $529B and Arcutis Biotherapeutics (ARQT) $3.4B. Over the last year, with dividends, ABBV moved +32.5% and ARQT +11.3%. The P/E is 51.4 for ABBV and 115.4 for ARQT. Dividend yield: ABBV 2.31%, ARQT none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$529B

    ARQT$3.4B

    ABBV is 153 times ARQT

  • Revenue, 12 months

    ABBV$66.0B

    ARQT$509M

    ABBV is 130 times ARQT

  • Net income, 12 months

    ABBV$10.3B

    ARQT$30M

    ABBV is 346 times ARQT

  • Operating margin

    ABBV32.2%

    ARQT6.9%

    25.3 points apart

  • ROIC

    ABBV25.7%

    ARQT9.0%

    16.7 points apart

  • P/E

    ABBV51.4

    ARQT115.4

    ARQT is 2.2 times ABBV

  • Dividend yield

    ABBV2.3%

    ARQT0.0%

    2.3 points apart

  • 5-year return

    ABBV+205.8%

    ARQT+37.4%

    168.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+205.8%

ARQT+37.4%

010020030020222023202420252026
Returns by period
PeriodABBVWith dividendsARQTWith dividends
1 year since November 14, 2025+32.5%Price +28.6%+11.3%Price +11.3%
3 years since November 16, 2023+139.0%+33.7% a yearPrice +116.1%+1,326.7%+142.5% a yearPrice +1,326.7%
5 years since November 15, 2021+205.8%+25.1% a yearPrice +155.8%+37.4%+6.6% a yearPrice +37.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieARQTArcutis Biotherapeutics

Valuation

ABBVARQT
Valuation
Price$299.19$27.82
Market value$529B$3.4B
Enterprise value (EV)$599B–
P/E51.4115.4
P/E, 5-year median57.0–
P/B–14.1
EV/EBIT28.2–
Free cash flow yield3.6%1.7%

Results and growth

ABBVARQT
Results and growth
Revenue, 12 months$66.0B$509M
Net income, 12 months$10.3B$30M
Free cash flow, 12 months$18.9B$60M
Earnings per share, 12 months$5.81$0.24
Revenue growth, year on year8.6%91.3%
Revenue growth a year, past+5.9%over 5 years–
EPS growth a year, past-2.8%over 5 years–

Margins and returns on capital

ABBVARQT
Margins and returns on capital
Gross margin73.7%91.2%
Operating margin32.2%6.9%
Net margin15.7%5.9%
ROIC25.7%9.0%
ROE–14.9%

Balance sheet

ABBVARQT
Balance sheet
Cash$10.8B$259M
Total debt$80.9B–
Net debt / EBITDA3.2–
Interest cover7.1×2.6×

Dividends and buybacks

ABBVARQT
Dividends and buybacks
Dividend yield2.3%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%–
Shareholder yield2.5%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or ARQT

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Arcutis Biotherapeutics?

By market value, AbbVie ($529B) is about 153.3 times Arcutis Biotherapeutics ($3.4B), at today's prices.

How did ABBV and ARQT stock do over the last 5 years?

Since November 15, 2021, ABBV's price moved +155.8% and ARQT's +37.4%. With dividends: ABBV +205.8% (+25.1% a year), ARQT +37.4% (+6.6% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or ARQT?

The dividend yield at today's price is 2.31% for AbbVie and none for Arcutis Biotherapeutics. Over the last twelve months they paid $6.92 and – per share.

What is the P/E of ABBV and ARQT?

At today's price, the P/E is 51.4 for ABBV and 115.4 for ARQT. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, AbbVie or Arcutis Biotherapeutics?

Over the last twelve months, the net margin was 15.7% for AbbVie and 5.9% for Arcutis Biotherapeutics, and the operating margin 32.2% and 6.9%. Revenue was $66.0B and $509M.

Which is the better investment, AbbVie or Arcutis Biotherapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.